Overall, the safety and efficacy findings in this study are consistent with the results of the OPTiM trial, which compared intralesional T‐VEC with subcutaneous GM‐CSF in non‐Asian patients with unresectable stage IIIB–IV melanoma.27 Here, CSF2 is linked to melanoma.